48 patients participated in a double-blind placebo-controlled study conducted to evaluate the efficacy of ribavirin in the treatment of herpes simplex virus genital infection. Study design did not allow a conclusion regarding usefulness of the drug in preventing recurrences. Ribavirin treatment (800 mg/day p.o) for 10 days reduced disease severity and promoted recovery as compared with placebo treatment.
No takes yet. Share an insight, caveat, or question.
Bierman et al. (2009) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: